JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
Select period of competence
Q2 2024 Results Presentation
Q1 2024 Results Presentation
FY 2023 Results Presentation
9M 2023 Results Presentation
Third Quarter results confirm guidance for Fiscal Year 2023
H1 2023 Results Presentation
Revenues at constant perimeter of consolidation and ex-Covid up 5% at CER in Q2. FY 2023 Guidance Confirmed
Q1 2023 Results Presentation
Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023
FY 2022 Results Presentation
REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE
9M 2022 Results Presentation
Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards
H1 2022 Results Presentation
Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards
Q1 2022 Results Presentation
Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards
FY 2021 Results Presentation
DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021
9M 2021 Results Presentation
DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021
H1 2021 Results Presentation
DiaSorin: Revenues and Profitability continue upward momentum in the First Half of 2021, with Guidance raised following the acquisition of Luminex
Q1 2021 Results Presentation
DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021
FY 2020 Results Presentation
Revenues, Profitability and Cash Flow Generation hit record highs in 2020
9M 2020 Results Presentation
North America growth drives up revenues and profitability in the first 9 months of 2020
H1 2020 Results Presentation
North America business growth drives Group revenues and profitability in H1 2020
Q1 2020 Results Presentation
DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic
FY 2019 Results Presentation
DiaSorin - Cash flow generation and net profit hit record highs in 2019
9M 2019 Results Presentation
Record free cash flow generation along with growth in revenues and profitability for DiaSorin in the first 9 months of 2019
H1 2019 Results Presentation
DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability.
Q1 2019 Results Presentation
DiaSorin Group reports growth in profitability and strong free cash flow generation in the first quarter 2019
FY 2018 Results Presentation
Growth in revenues, profitability and net profit in 2018
9M 2018 Results Presentation
DiaSorin Group reports growth in revenues and net profit in the first nine months of 2018
H1 2018 Results Presentation
The Board of Directors approves the results for the first half of 2018
Q1 2018 Results Presentation
The DiaSorin Group reports growth in revenues and profitability in the first quarter 2018
FY 2017 Results Presentation
DiaSorin: FY 2017 Results
FY 2016 Results Presentation
The Board of Directors approves the results for FY'16
FY 2015 Results Presentation
The Board of Directors approves the results for FY'15
FY 2014 Results Presentation
The Board of Directors approves the results for FY'14